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Abstract
Background: Elevation of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) is prominent in acute
dengue illness. The World Health Organization (WHO) 2009 dengue guidelines defined AST or ALT$1000 units/liter (U/L) as
a criterion for severe dengue. We aimed to assess the clinical relevance and discriminatory value of AST or ALT for dengue
hemorrhagic fever (DHF) and severe dengue.
Methodology/Principal Findings: We retrospectively studied and classified polymerase chain reaction positive dengue
patients from 2006 to 2008 treated at Tan Tock Seng Hospital, Singapore according to WHO 1997 and 2009 criteria for
dengue severity. Of 690 dengue patients, 31% had DHF and 24% severe dengue. Elevated AST and ALT occurred in 86% and
46%, respectively. Seven had AST or ALT$1000 U/L. None had acute liver failure but one patient died. Median AST and ALT
values were significantly higher with increasing dengue severity by both WHO 1997 and 2009 criteria. However, they were
poorly discriminatory between non-severe and severe dengue (e.g., AST area under the receiver operating characteristic
[ROC] curve=0.62; 95% confidence interval [CI]: 0.57–0.67) and between dengue fever (DF) and DHF (AST area under the
ROC curve=0.56; 95% CI: 0.52–0.61). There was significant overlap in AST and ALT values among patients with dengue with
or without warning signs and severe dengue, and between those with DF and DHF.
Conclusions: Although aminotransferase levels increased in conjunction with dengue severity, AST or ALT values did not
discriminate between DF and DHF or non-severe and severe dengue.
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Introduction
Dengue is a mosquito-borne arboviral infection endemic to most
tropical and subtropical countries[1].Elevationoftheliver enzymes
aspartate aminotransferase (AST) and alanine aminotransferase
(ALT) is common in acute dengue illness, occurring in 65–97%
[2,3,4,5] of dengue patients, peaking during the convalescent period
of illness (days 7–10) [2,4,6]. In dengue-endemic countries, dengue
is an important cause of acute viral hepatitis [7].
Elevated AST and ALT levels have been associated with
bleeding [2,4,6] and dengue hemorrhagic fever (DHF) [3,8]. Liver
failure has been recognized as a complication and unusual
manifestation of dengue [9,10] but occurred infrequently in 3 of
270 patients in Taiwan [6] and 5 of 644 patients in Vietnam [4].
In Malaysia, 8 of 20 pediatric DHF patients developed liver
failure, 1 died, and the rest recovered completely [11]. In
Singapore, AST or ALT levels were not independent predictors
of DHF in 1973 adult dengue patients [12].
In 2009, the World Health Organization (WHO) revised its
dengue guidelines and proposed severe organ impairment as one
category of severe dengue in addition to severe plasma leakage and
severe bleeding [1]. Severe liver involvement was defined as AST
or ALT$1000 units/liter (U/L). In Taiwan, AST.10 times the
upper limit of normal (ULN) occurred in 11% of dengue patients
[6], while in Brazil this occurred in 4% of their cohort [3]. In this
study, we aimed to evaluate the clinical relevance of elevated AST
and ALT levels and correlate liver aminotransferase levels with
dengue severity according to WHO 1997 and 2009 classifications.
Methods
All laboratory-confirmed dengue patients identified from our
hospital microbiology database and treated using a standardized
dengue clinical care path at the Department of Infectious Diseases,
Tan Tock Seng Hospital (TTSH), Singapore from 2006 to 2008
were retrospectively reviewed for demographic, serial clinical and
laboratory, radiological, treatment, and outcome data. These cases
were positive by real-time polymerase chain reaction (PCR) [13].
We included patients with only positive dengue serology in only
subgroup analyses, as we did not have paired sera, and other
etiologies for elevated AST and ALT could not be excluded
without more extensive evaluation.
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from the entire clinical course as dengue fever (DF), DHF, or
dengue shock syndrome (DSS) using WHO 1997 classifications
[9]. Dengue fever classification requires fever and at least two of
the following: headache, eye pain, myalgia, arthralgia, rash,
bleeding, and leukopenia. Dengue hemorrhagic fever requires all
of the following: fever, platelet count #100610
9/liter, bleeding,
and plasma leakage [9]. Dengue shock syndrome is a case of DHF
with either tachycardia and pulse pressure ,20 mmHg or systolic
blood pressure ,90 mmHg [9].
Cases were also categorized as dengue without warning signs
(WS), dengue with WS, or severe dengue using WHO 2009
classifications [1]. Dengue (WHO 2009) requires fever and two of
the following: nausea, vomiting, rash, aches and pains, leukopenia,
or any warning sign [1]. Warning signs include abdominal pain or
tenderness, persistent vomiting, clinical fluid accumulation,
mucosal bleeding, lethargy or restlessness, hepatomegaly, or
hematocrit rise ($20%) with rapid drop in platelet count
(,50,000/liter) [1,14]. We modified the WHO 2009 warning
sign of rise in hematocrit concurrent with rapid drop in platelet
count by quantifying it as hematocrit $20% concurrent with
platelet count ,50,000/liter, as this was shown to correlate
significantly with dengue death in our adult dengue death study
[14]. Severe dengue includes severe plasma leakage, severe
bleeding, and severe organ impairment [1].
We performed a subgroup analysis for median maximum AST
and ALT values stratified by febrile (days 1–3 of illness), critical
(days 4–6), and convalescent (days 7–10) phases as defined by
WHO 2009 [1] and compared across dengue severity classification
according to WHO 1997 [9] and 2009 [1].
We excluded severe dengue due to isolated elevation of AST or
ALT$1000 U/L from our definition of severe dengue outcome,
as this would be a confounder in assessing the relevance of AST or
ALT levels in defining dengue severity. Patients had AST/ALT
taken at presentation and then throughout hospitalization at the
physician’s discretion. Maximum AST and ALT values recorded
at a median of 4 days of illness (interquartile range [IQR]: 3–5
days) were used in this analysis. Those with pre-existing liver
diseases were excluded. At TTSH, the ULN for AST is 41 U/L;
for ALT, it is 63 U/L for males and 54 U/L for females.
We assessed the clinical relevance of elevated AST or ALT
levels using four liver failure criteria—two for acute liver failure,
and two that determine prognosis from chronic liver disease. The
American Association for the Study of Liver Diseases (AASLD)
recommends defining acute liver failure in a patient as:
international normalized ratio (INR)$1.5, any degree of altered
mental status, and illness ,26 weeks in duration without pre-
existing cirrhosis [15]. The King’s College criteria assess prognoses
in those with acute liver failure; the criteria are: prothrombin time
.100 seconds or 3 of the following: age .40 years, prothrombin
time .50 seconds, serum bilirubin .18 mg/dL, time from
jaundice to encephalopathy .7 days [16]. The model for end-
stage liver disease (MELD) determines three-month mortality
based on the following formula: 3.86(log serum bilirubin [mg/
dL])+11.26(log INR)+9.66(log serum creatinine [mg/dL])+6.4
[17]. The Child-Pugh criteria include assessment of degree of
ascites, serum bilirubin and albumin, prothrombin time, and
encephalopathy to determine one- and two-year survival [18].
The Mann-Whitney U and Kruskal-Wallis tests were used to
determine statistical significance for continuous variables, and chi-
square or Fisher’s exact test for categorical variables. Statistical
tests were conducted at the 5% level of significance. Receiver
operating characteristic (ROC) curves showing the area under the
curve (AUC) were generated to determine the discriminatory
performance of aminotransferase values. All statistical analyses
were performed using Stata 10 (Stata Corp., College Station, TX).
This was a retrospective study involving data collection from
medical records. All patient data were anonymized during
analysis. This study was approved by the Institutional Review
Board, National Healthcare Group, Singapore [DSRB E/08/
567].
Results
From 2006 to 2008, 690 dengue PCR positive cases were
reviewed. Males comprised 493 (71%) of the cases, and the median
age of the cohort was 35 years (IQR: 27–43 years). A Charlson
comorbidity index $3, which predicts increased one-year mortal-
ity [19], was noted in 5 (0.7%) patients. With WHO 1997
classification, 62% had DF, 31% DHF, and 7% DSS. With WHO
2009 classification, 14% had dengue, 62% had dengue with
warning signs, and 24% had severe dengue. Hence, by WHO
1997 classification, 38% of patients with DHF/DSS needed close
monitoring, while by WHO 2009 classification, 86% of patients
with warning signs or severe dengue required close monitoring.
Median length of illness from onset to hospital presentation was
4 days (IQR: 3–5 days), while median length of hospital stay was 5
days (IQR: 4–6 days). Intravenous fluid was administered to 641
(93%) and platelet transfusion to 86 (12%). Intensive care unit
(ICU) admission was required in 3 patients, and death occurred in
1 patient due to pneumonia.
(1) Elevation of AST/ALT and risk of liver failure
Overall, 595 (86%) had AST above the ULN, and 316 (46%)
had ALT above the ULN. Seven patients (1.0%) had severe
dengue according to WHO 2009 criteria concurrent with AST or
ALT$1000 U/L while three additional patients had severe
dengue due to AST or ALT$1000 U/L only. Of the former
seven patients, 86% had severe plasma leakage, 29% had severe
bleeding, and none had severe organ impairment other than
isolated AST or ALT$1000 U/L. Among the 3 patients admitted
to the ICU, AST or ALT values were above the ULN but below
1000 U/L.
No patients in our cohort developed acute liver failure under
AASLD or King’s College criteria. With Child-Pugh scoring, 2
(0.3%) belonged to Child-Pugh class C. With MELD scoring,
predicted three-month mortality of 6% were identified in 68 (10%)
Author Summary
Dengue is a global public health problem, as the incidence
of the disease has reached hyperendemic proportions in
recent decades. Infection with dengue can cause acute,
febrile illness or severe disease, which can lead to plasma
leakage, bleeding, and organ impairment. One of the most
prominent clinical characteristics of dengue patients is
increased aspartate and alanine aminotransferase liver
enzyme levels. The significance of this is uncertain, as it is
transient in the majority of cases, and most patients
recover uneventfully without liver damage. In this study,
we characterized this phenomenon in the context of
dengue severity and found that, although liver enzyme
levels increased concurrently with dengue severity, they
could not sufficiently discriminate between dengue fever
and dengue hemorrhagic fever or between non-severe
and severe dengue. Therefore clinicians may need to use
other parameters to distinguish dengue severity in
patients during early illness.
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two patients who were Child-Pugh class C also had a predicted
19.6% three-month mortality using MELD scoring; they both had
DSS and severe dengue.
(2) Dengue severity and AST/ALT values
Median AST and ALT values for dengue without warning
signs, dengue with warning signs, and severe dengue (Table 1)
were 83.5 U/L, 92 U/L, and 124 U/L, respectively (p,0.001);
median ALT values were 49 U/L, 53 U/L, and 73.5 U/L
(p=0.002). Table 2 shows median AST and ALT values for
patients with DF, DHF, and DSS. Median AST values for these
categories were 93 U/L, 103 U/L, and 137.5 U/L, respectively
(p=0.01), and median ALT values were 52 U/L, 60 U/L, and
74 U/L (p=0.05).
In a separate analysis of our serology-positive cohort (n=1487),
median AST values for dengue without WS, dengue with WS, and
severe dengue were 84 U/L, 114 U/L, and 147 U/L (p,0.001).
Median ALT values were 56 U/L, 73 U/L, and 97.5 U/L
(p=0.01). For patients with DF, DHF, and DSS, median AST
values were 105 U/L, 130 U/L, and 129 U/L (p,0.001), and
median ALT values were 68 U/L, 78 U/L, and 85.5 U/L
(p=0.008).
In other hemorrhagic fevers, higher AST:ALT ratios correlated
with disease fatality [20]. In our PCR-positive cohort, median
AST:ALT ratios for DF, DHF, and DSS were 1.68, 1.68, and 1.88
(p=0.29) and for dengue without WS, dengue with WS, and
severe dengue, they were 1.60, 1.68, and 1.78 (p=0.10),
respectively.
(3) Aminotransferase levels stratified by febrile, critical
and convalescent phases
The majority of our patients’ maximum AST and ALT values
were recorded during febrile (n=258) and critical (n=377) phases
of acute dengue illness. By WHO 2009 dengue severity
classification, the median AST and ALT values were significantly
higher for severe dengue compared to dengue with and without
warning signs during both the febrile and critical phases but not
the convalescent phase (Table 3). By WHO 1997 classification, the
median AST and ALT values were significantly higher for DHF
Table 1. AST and ALT distributions by WHO 2009 dengue classification.
Dengue without warning signs (n=100) Dengue with warning signs (n=426) Severe dengue (n=164) P value
AST, U/L 83.5 (48.5–153.5) 92 (57–167) 124 (75–244.5) ,0.001
ALT, U/L 49 (28–113) 53 (32–100) 73.5 (40–147.5) 0.002
AST=aspartate aminotransferase.
ALT=alanine aminotransferase.
U/L=units/liter.
All values are expressed as median (interquartile range).
doi:10.1371/journal.pntd.0001676.t001
Table 2. AST and ALT distributions by WHO 1997 dengue classification.
Dengue fever (n=429) Dengue hemorrhagic fever (n=211) Dengue shock syndrome (n=50) P value
AST, U/L 93 (55–165) 103 (66–203) 137.5 (63–265) 0.01
ALT, U/L 52 (31–107) 60 (37–118) 74 (35–167) 0.05
AST=aspartate aminotransferase.
ALT=alanine aminotransferase.
U/L=units/liter.
All values are expressed as median (interquartile range).
doi:10.1371/journal.pntd.0001676.t002
Table 3. AST and ALT distributions by dengue phase and WHO 2009 classification.
Phase of illness Dengue Dengue with warning signs Severe dengue P value
AST, U/L Febrile phase (days 1–3) 56.5 (39–107) 68 (48–103) 106 (57.5–167) 0.004
Critical phase (days 4–6) 93 (61–158) 108.5 (64–189.5) 143.5 (82–265) 0.004
Convalescent phase (days 7–10) 196 (112–227) 278 (171–413) 255 (137–439) 0.56
ALT, U/L Febrile phase (days 1–3) 31.5 (22–50) 45 (24–65) 56 (27.5–107.5) 0.02
Critical phase (days 4–6) 54.5 (34.5–118.5) 60.5 (34.5–105) 72 (40–165) 0.05
Convalescent phase (days 7–10) 130 (60–223) 215.5 (150.5–375) 131 (97–301) 0.22
AST=aspartate aminotransferase.
ALT=alanine aminotransferase.
U/L=units/liter.
All values are expressed as median (interquartile range).
doi:10.1371/journal.pntd.0001676.t003
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Phase of illness Dengue fever Dengue hemorrhagic fever Dengue shock syndrome P value
AST, U/L Febrile phase (days 1–3) 63 (41–111.5) 84.5 (59.5–139) 60 (41–107) 0.02
Critical phase (days 4–6) 101.5 (67–190.5) 123 (66–211) 163.5 (86–285.5) 0.12
Convalescent phase (days 7–10) 257.5 (140–296) 286 (188–413) 229 (137–476) 0.65
ALT, U/L Febrile phase (days 1–3) 39.5 (24–65) 50.5 (34–80) 31.5 (19–67) 0.03
Critical phase (days 4–6) 58 (36–111) 62.5 (35–120) 69.5 (42–146.5) 0.57
Convalescent phase (days 7–10) 171 (108–303) 212 (130–334) 301 (104–473) 0.44
AST=aspartate aminotransferase.
ALT=alanine aminotransferase.
U/L=units/liter.
All values are expressed as median (interquartile range).
doi:10.1371/journal.pntd.0001676.t004
Figure 1. Discriminatory performance of AST and ALT for differentiating severe dengue from non-severe dengue. AST=aspartate
aminotransferase. ALT=alanine aminotransferase. AUC=area under the curve.
doi:10.1371/journal.pntd.0001676.g001
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convalescent phases (Table 4).
(4) Does a threshold AST or ALT value defining severe
dengue exist?
In order to determine the reliability of AST and ALT values in
defining dengue severity, ROC curves for AST and ALT against
severe dengue excluding isolated transaminitis were determined
(Figure 1). The AUC for AST was 0.62 (95% confidence interval
[CI]: 0.57–0.67) and for ALT, 0.60 (95% CI: 0.54–0.64). This
demonstrates that AST or ALT levels are insufficient to
differentiate among the WHO 2009 dengue classifications. They
were also poorly discriminatory between DF and DHF, as the
areas under the curve (AUC) for AST and ALT were 0.56 (95%
CI: 0.52–0.61) and 0.55 (95% CI: 0.51–0.59), respectively
(Figure 2). In our serology-positive cohort, the AUC values for
AST and ALT were 0.56 and 0.54 for differentiating between DF
and DHF. The AUC values for severe and non-severe dengue
were 0.64 and 0.60 for AST and ALT, respectively.
The box plots in Figure 3 for the distributions of AST values
show considerable overlap among the liver enzyme values for
those with dengue with and without warning signs, and severe
dengue. Because there were extreme outliers in our cohort, only
those with AST below 1000 U/L were included in these plots.
Figure 4 shows overlapping AST values among those with DF and
DHF. Similarly, considerable overlap was observed in ALT values
for patients with dengue with and without warning signs, and
severe dengue, as well as for DF versus DHF (data not shown).
Figure 2. Discriminatory performance of AST and ALT for differentiating dengue hemorrhagic fever from dengue fever.
AST=aspartate aminotransferase. ALT=alanine aminotransferase. AUC=area under the curve.
doi:10.1371/journal.pntd.0001676.g002
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Our analysis showed that liver aminotransferase levels were
associated with but did not adequately differentiate between
dengue severity. Although median AST and ALT values were
significantly higher in those with DHF/DSS versus DF, and severe
dengue versus non-severe dengue, very few (1.0%) had AST or
ALT$1000 U/L. Notably, none developed liver failure, and
death occurred in only 1 patient (0.1%). The majority of patients
recovered uneventfully.
The lack of acute liver failure in our study was not unusual, as
the incidence of acute liver failure in dengue patients was 1.1% in
studies by Trung and Kuo [4,6]. The largest study to date reported
no acute fulminant hepatitis [3]. In contrast to these adult studies,
it is noteworthy that in dengue-endemic countries, dengue may be
an important cause of acute liver failure in children [21,22].
While some studies have shown that AST and ALT values differ
between DF and DHF [3,4,8], few studies support AST or ALT as
an independent predictor of DHF [23]. Two studies in Singapore
found liver aminotransferase levels to be significantly elevated
among DF and DHF patients [12] and survivors and non-
survivors of dengue [24] on univariate analysis, but this association
was lost after adjusting for confounders on multivariate analysis.
Trung et al. showed significant differences comparing other
febrile illness, dengue without plasma leakage, and dengue with
plasma leakage with and without shock during critical and
convalescent phases for AST but during critical phase for ALT
only [4]. We made the novel finding that liver aminotransferase
Figure 3. Distribution of maximum AST values during hospitalization for those with AST,1000 U/L: WHO 2009 classifications. The
25
th and 75
th percentiles are represented by the lower and upper horizontal edges of the box, respectively, while the whiskers represent the 5
th and
95
th percentiles. The median is indicated by the horizontal line inside the box. WS=warning signs. AST=aspartate aminotransferase. U/L=units/liter.
doi:10.1371/journal.pntd.0001676.g003
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febrile phase. For DHF by WHO 1997 classification, both AST and
ALT were significantly higher during the febrile phase compared to
DF or DSS, and for severe dengue by WHO 2009, AST and ALT
were significantly higher during the febrile and critical phases.
The impact of co-infection with hepatitis viruses or concomitant
hepatotoxic drugs was not assessed in our retrospective study,
although we did exclude those with known liver comorbidities.
Kuo et al. found that hepatitis B or C did not increase the extent of
liver aminotransferase elevation in a retrospective adult dengue
study in Taiwan [6]. In contrast, Trung et al. found that hepatitis
B co-infection modestly increased ALT levels without significant
clinical impact in a prospective adult dengue study in Vietnam [4].
Tang et al. showed that dengue and hepatitis B co-infected
patients showed an aberrant cytokine secretion profile compared
with those with dengue alone. [25]. In Singapore, seroprevalence
for hepatitis B was 2.8% [26] and hepatitis C 0.37% [27].
The etiology of elevated aminotransferase levels during acute
dengue illness is unclear since AST is expressed in the heart,
skeletal muscle, red blood cells, kidneys, brain, and liver, while
ALT is secreted primarily by the liver [28,29]. Because dengue
infection can cause acute damage to these non-hepatic tissue types
that express AST, raised aminotransferase levels may not be
entirely due to severe liver involvement. It is therefore possible that
the patients with high AST levels were also more likely to be
classified as severe dengue under the 2009 criteria due to the
common pathways to non-hepatic tissue damage, even though
there is no association with poorer outcome.
Figure 4. Distribution of maximum AST values during hospitalization for those with AST,1000 U/L: WHO 1997 classifications.
AST=aspartate aminotransferase. U/L=units/liter. DF=dengue fever. DHF=dengue hemorrhagic fever. DSS=dengue shock syndrome.
doi:10.1371/journal.pntd.0001676.g004
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alanine aminotransferase values were tracked according to clinical
judgment rather than at regular intervals during illness. We did
not have dengue serotype data for each patient, but in 2006,
DENV-1 was predominant in Singapore with a switch to DENV-2
in 2007–2008 [30]. Serology-positive cases were not included in
primary analyses because our clinical laboratory used a rapid
diagnostic test with potential for false positive results [31], we did
not have paired sera to confirm dengue diagnosis [9], and not
every patient with elevated AST or ALT was comprehensively
evaluated for other etiologies of viral and non-viral hepatitis.
Although serology-positive cases presented later during illness, we
saw no difference in outcome. Five serology-positive patients
(0.34%) required ICU admission versus 0.43% of PCR-positive
cases, while four patients (0.27%) died in the serology-positive
cohort, versus 1 patient (0.14%) among PCR-positive cases.
However, relative data accuracy in our retrospective study was
made possible by using a standardized dengue clinical care path.
Another limitation of this study is the relatively few cases with
substantially elevated liver aminotransferase levels. At the same
time, since our cohort comprised primarily adults, additional
studies in pediatric populations will be useful to confirm our
findings.
In patients with DHF/DSS or severe dengue, early diagnosis
and proper management may improve outcome in most patients
without comorbidities. However, in resource-limited countries,
patients with severe disease may present late to the hospital with
shock, with or without organ impairment at the time of admission.
Our study highlights that early diagnosis and proper management
of dengue patients may lead to excellent prognosis without organ
injury.
In conclusion, elevated aminotransferase levels were associated
with DHF/DSS and severe dengue in our cohort of adult patients
with confirmed dengue. However, no threshold values discrimi-
nated between DF and DHF or between severe dengue and non-
severe dengue.
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